Abstract Title:

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.

Abstract Source:

Neurology. 2005 Dec 13;65(11):1834-6. PMID: 16344537

Abstract Author(s):

K L Ferrante, J Shefner, H Zhang, R Betensky, M O'Brien, H Yu, M Fantasia, J Taft, M F Beal, B Traynor, K Newhall, P Donofrio, J Caress, C Ashburn, B Freiberg, C O'Neill, C Paladenech, T Walker, A Pestronk, B Abrams, J Florence, R Renna, J Schierbecker, B Malkus, M Cudkowicz

Article Affiliation:

Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. [email protected]

Abstract:

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

Study Type : Human Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.